Daratumumab (PBS) (Anti-Human CD38) (CAS: 945721-28-8)
Daratumumab is a human IgG1κ monoclonal antibody that targets CD38, a protein highly expressed on multiple myeloma cells. It works by inducing tumor cell death through several mechanisms, including antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP).
Key Features:
- Target: Binds specifically to CD38 on multiple myeloma cells.
- Mechanism of Action: Kills tumor cells via ADCC, CDC, and ADCP.
- Therapeutic Use: Approved for treating multiple myeloma.
Applications:
- Cancer Research: Develops antibody-drug conjugates (ADCs) that target CD38-expressing tumors for more precise treatment.
- Therapeutic Development: Used in creating ADCs that deliver cytotoxic drugs directly to CD38-positive cancers.
Handling and Storage:
- Storage: Store at -20°C, protected from light.
- Precautions: Use personal protective equipment and handle in a well-ventilated area.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
